ES2192128B1 - HUMAN MONOCLONAL ANTIBODY THAT SPECIFICALLY RECOGNIZES THE CD69 HUMAN MOLECULA, AND ITS USE IN THERAPY. - Google Patents
HUMAN MONOCLONAL ANTIBODY THAT SPECIFICALLY RECOGNIZES THE CD69 HUMAN MOLECULA, AND ITS USE IN THERAPY.Info
- Publication number
- ES2192128B1 ES2192128B1 ES200100997A ES200100997A ES2192128B1 ES 2192128 B1 ES2192128 B1 ES 2192128B1 ES 200100997 A ES200100997 A ES 200100997A ES 200100997 A ES200100997 A ES 200100997A ES 2192128 B1 ES2192128 B1 ES 2192128B1
- Authority
- ES
- Spain
- Prior art keywords
- human
- monoclonal antibody
- molecule
- therapy
- specifically recognizes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102100025137 Early activation antigen CD69 Human genes 0.000 title abstract 4
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 3
- 210000004698 lymphocyte Anatomy 0.000 abstract 3
- 108010092574 CD69 antigen Proteins 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 2
- 210000004408 hybridoma Anatomy 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 241001529936 Murinae Species 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 238000010166 immunofluorescence Methods 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 210000004989 spleen cell Anatomy 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 238000011830 transgenic mouse model Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Anticuerpo monoclonal humano haIM-29 que reconoce la molécula humana CD69, y su uso en terapia humana. Un nuevo hibridoma, designado H69, productor de un anticuerpo monoclonal humano hAIM- 29 (de isotipo IgM / lambda). El anticuerpo reconoce de forma específica a la molécula humana CD69, que es un antígeno de activación muy temprano linfocitario. El hibridoma H69 se generó por fusión de células del mieloma murino NSO con células de bazo de un ratón transgénico portador de secuencias de inmunoglobulinas humanas que había sido inmunizado con una suspensión de células de rata transfectadas con la molécula humana CD69. El clon fue seleccionado por su patrón de reconocimiento celular por inmunofluorescencia indirecta frente a las células de rata transfectadas y frente a linfocitos activados humanos. La presente invención podría utilizarse para tratamiento de patologías humanas que conlleve gran activación linfocitaria (enfermedades autoinmunes como la artritis reumatoide u otras patologías de tipo inflamatorio).HaIM-29 human monoclonal antibody that recognizes the human CD69 molecule, and its use in human therapy. A new hybridoma, designated H69, producer of a human monoclonal antibody hAIM-29 (IgM / lambda isotype). The antibody specifically recognizes the human molecule CD69, which is a very early lymphocyte activation antigen. The H69 hybridoma was generated by fusion of NSO murine myeloma cells with spleen cells of a transgenic mouse carrying human immunoglobulin sequences that had been immunized with a suspension of rat cells transfected with the human CD69 molecule. The clone was selected for its pattern of cellular recognition by indirect immunofluorescence against transfected rat cells and against human activated lymphocytes. The present invention could be used for the treatment of human pathologies that entails great lymphocyte activation (autoimmune diseases such as rheumatoid arthritis or other inflammatory diseases).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200100997A ES2192128B1 (en) | 2001-04-27 | 2001-04-27 | HUMAN MONOCLONAL ANTIBODY THAT SPECIFICALLY RECOGNIZES THE CD69 HUMAN MOLECULA, AND ITS USE IN THERAPY. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200100997A ES2192128B1 (en) | 2001-04-27 | 2001-04-27 | HUMAN MONOCLONAL ANTIBODY THAT SPECIFICALLY RECOGNIZES THE CD69 HUMAN MOLECULA, AND ITS USE IN THERAPY. |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2192128A1 ES2192128A1 (en) | 2003-09-16 |
ES2192128B1 true ES2192128B1 (en) | 2005-01-01 |
Family
ID=28051947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES200100997A Expired - Fee Related ES2192128B1 (en) | 2001-04-27 | 2001-04-27 | HUMAN MONOCLONAL ANTIBODY THAT SPECIFICALLY RECOGNIZES THE CD69 HUMAN MOLECULA, AND ITS USE IN THERAPY. |
Country Status (1)
Country | Link |
---|---|
ES (1) | ES2192128B1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2244270A1 (en) * | 2003-01-31 | 2005-12-01 | Pilar Universidad Autonoma De Madrid | Immune regulation based on the targeting of early activation molecules |
WO2004069183A2 (en) | 2003-01-31 | 2004-08-19 | Albor Biologics, Inc. | Immune regulation based on the targeting of early activation molecules |
DK2119452T3 (en) * | 2006-12-26 | 2020-04-20 | Ct Inmunologia Molecular | Pharmaceutical composition comprising an anti-CD6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis |
EA201001467A1 (en) | 2008-03-14 | 2011-06-30 | Биокон Лимитед | MONOCLONAL ANTIBODY AND METHOD OF ITS USE |
KR102034757B1 (en) | 2013-07-23 | 2019-10-21 | 바이오콘 리미티드 | Use of a cd6 binding partner and method based thereon |
EP3529274B1 (en) | 2016-10-21 | 2024-04-17 | Biocon Limited | A monoclonal antibody and a method of use for the treatment of lupus |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
CA2761116A1 (en) * | 1995-04-27 | 1996-10-31 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
-
2001
- 2001-04-27 ES ES200100997A patent/ES2192128B1/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
SANCHO D. et al. Functional Analysis of Ligand-Binding and Signal Transduction Domains of CD69 and CD23 C-Type Lectin Leukocyte Receptors. J. Immunol., Octubre 2000, Vol. 165, Nº 7, páginas 3868-3875. * |
Also Published As
Publication number | Publication date |
---|---|
ES2192128A1 (en) | 2003-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1425389E (en) | Human antibodies specific for interleukin 15 (il-15) | |
HRP20181069T1 (en) | Il-17 antagonistic antibodies | |
ES2514495T3 (en) | Humanized anti-interleukin-18 modified antibodies | |
RU2010130994A (en) | AGENTS AGAINST TARGET CELLS AIMED AT CD138 AND THEIR APPLICATION | |
AR079458A2 (en) | CHEMICAL MONOCLONAL ANTIBODY THAT JOINS CD45 | |
PE20120835A1 (en) | ANTI-TNF-ALPHA ANTIBODIES AND THEIR USES | |
NZ568403A (en) | CD20-specific antibodies and methods of employing same | |
PE20030104A1 (en) | HUMAN ANTIBODIES TO CD154 | |
RU2016151645A (en) | SPECIFIC HETERODIMERIC DIANTISTS AND THEIR APPLICATION | |
PE20090689A1 (en) | ANTIBODIES OF ANTAGONIST OX40 AND ITS USE IN THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | |
RU2005132389A (en) | HUMANIZED ANTI-CD4 ANTIBODY WITH IMMUNO DEPRESSIVE PROPERTIES | |
EP2639242A3 (en) | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease | |
LT2005099A (en) | Antibodies directed to monoclonal chemo-atractant protein-1 (mcp-1) and uses thereof | |
EA200500835A1 (en) | HUMAN MONOCLONAL ANTIBODIES AGAINST CD25 | |
TW200513261A (en) | Antibodies against interleukin-1 receptor and uses thereof | |
WO2007103469A3 (en) | Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease | |
DK0812333T3 (en) | Bispecific antibody which is effective in treating B-cell lymphoma and cell line | |
RU2007139953A (en) | ANTIBODIES TO CCR5 AND THEIR APPLICATION | |
NZ604090A (en) | Human anti-b7rp1 neutralizing antibodies | |
DK1272527T3 (en) | Preparation of antibodies with ADCC via CD16 and especially monoclonal anti-Rhesus D antibodies | |
RU2010138567A (en) | ALPHA INTERFERON 1 RECEPTOR ANTIBODIES AND THEIR APPLICATION | |
NZ599497A (en) | Humanized antibodies to amyloid beta | |
RU2007140257A (en) | MONOCLONAL ANTI-CD20-ANTIBODY | |
RS51334B (en) | Cd20 antibodies with increased fc receptor binding affinity and effector function | |
RU2010149746A (en) | CROSS-REACTIVE ANTIBODIES ANTI-IL-17A / IL-17F AND WAYS OF THEIR APPLICATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EC2A | Search report published |
Date of ref document: 20030916 Kind code of ref document: A1 |
|
FG2A | Definitive protection |
Ref document number: 2192128B1 Country of ref document: ES |
|
FD2A | Announcement of lapse in spain |
Effective date: 20210803 |